anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ovarian cancer (OV) is a highly aggressive malignancy with poor prognosis due to recurrence and drug resistance. Therefore, it is imperative to investigate the key molecular mechanisms underlying OV progression in order to develop promising diagnostic and therapeutic interventions. Although the importance of hematological and neurological expressed 1 (HN1) protein in hemopoietic cell and neurological development has been well-established, its function in cancer, particularly in OV, remains uncertain. In this study, we compared the expression of HN1 in ovarian cancers and para-tumor tissues and predicted potential related signaling pathways through enrichment analysis. In order to confirm the role of HN1 in vitro and vivo, we carried out a variety of experiments including bioinformation analysis, colony formation, flow cytometry analysis, and subcutaneous tumor models. The results demonstrated that HN1 was upregulated in OV and was negatively associated with clinical prognosis. Moreover, we observed that HN1 enhances cell proliferation, migration, and drug resistance, while suppressing apoptosis in OV cells. Notably, we discovered that HN1 functions as a novel regulator of mTOR pathways. Our findings suggest that HN1-mediated mTOR regulation facilitates OV advancement and targeting HN1 could provide a promising therapeutic approach for clinical OV treatment.
A vehicle includes a vehicle computing system (VCS) and an adaptive cruise control module, a lane departure warning (LDW) module, a navigation system, or an alert mechanism (e.g., audible, visual or tactile). The VCS communicates with an activity tracking device worn by a vehicle driver. The activity tracking device detects and records biometric characteristics of the driver, and is capable of exchanging data with the VCS. The VCS generates at least one output signal based on data from the activity tracking device. An adaptive cruise control module may increase the distance between the vehicle and a tracking vehicle based on the signal. A navigation system may generate a recommended parking location based on a difference between step goals and current steps detected by the activity tracking device.
In the past decade, China has experienced fundamental decreases in the populations' physical activity levels, due to increasingly sedentary occupations and lifestyles. However, the transition to a Western lifestyle has not reached the entire Chinese population. The resulting wide range of between-person variation in physical activity provides an unparalleled opportunity for physical activity studies. Although physical activity measurement techniques have evolved considerably over the past years, the main obstacle in quantifying physical activity is the complexity of precisely measuring its individual components, particularly low to moderate-intensity activities.

Recently, investigators at Vanderbilt University, the Shanghai Cancer Institute, and the DCEG initiated two prospective population-based cohort studies: the Shanghai Women's Cohort and the Shanghai Men's Cohort. The aim of these studies is to prospectively examine the relations of diet, lifestyle, occupational, and environmental risk factors, as well as genetic variation, to cancer incidence among 75,000 women and 73,000 men, aged 40 to 70 years old, and residing in Shanghai, China. We propose to conduct a study among 600 women and men participating in these two cohort studies. The specific objectives of the current study are to develop a comprehensive physical activity questionnaire and to assess the validity and reliability of this instrument in the Shanghai cohorts using objective measures of physical activity/physical fitness: activity monitors, and the Modified Canadian Aerobic Fitness Test. In addition, we intend to evaluate whether different types and parameters of physical activity are associated with circulating levels of specific inflammatory markers that have been linked to cancer risk. The specific markers are C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor alpha (TNF-a). The impact of potentially confounding variables of the association between physical activity and inflammatory markers, such as recent exercise, use of anti-inflammatory drugs, and current or recent infections, will be carefully accounted for in the analysis.
Systems, methods, and instrumentalities are described herein for detecting failure mitigation associated with a surgical task. A device may perform a first autonomous function associated with a surgical task. Performing the first autonomous function may be associated with control feedback. The first autonomous function may be monitored by tracking one or more outputs associated with the control feedback. If the one or more outputs cross a failure threshold, the device may switch from performing the first autonomous function to performing a second autonomous function associated with the surgical task. The second autonomous function may be associated with failure mitigation feedback.
The present disclosure relates to cell cultured adipose tissue. In one embodiment, the cultured adipose tissue is produced by culturing adipose cells in a culture media in vitro, harvesting the adipose cells after a desired amount of adipose cells are produced, and aggregating the harvested adipose cells to provide the cultured adipose tissue. In some embodiments, aggregating the harvested adipose cells comprises mixing the harvested adipose cells with a hydrogel or binder in a three-dimensional (3D) mold. In other embodiments, aggregating the harvested adipose cells comprises cross-linking the harvested adipose cells in a 3D mold. The cultured adipose tissue have a defined 3D shape and a size on the macroscale. In some embodiments, the cultured adipose tissue may be a food product.
Participants will be monitored for 4 weeks. Halfway through the monitoring period, participants will be asked to turn on DNDWD.
PROBLEM TO BE SOLVED: To obtain an antiinflammatory medicine containing 2,4- dihydroxybenzophenone as an active ingredient and enabling the therapy of inflammation. SOLUTION: This antiinflammatory medicine contains 2,4- dihydroxybenzophenone as an active ingredient. The medicine is further suitably compounded with a diluent and/or an excipient, etc., and subsequently prepared into a preparation for oral, parenteral, transrectal or local administration. The medicine may orally be administered at a dose of 1-200mg (as the weight of the compound) up to twice a day for an adult. The medicine is parenterally suitably injected at a daily dose of 0.01-10mg, and also administered at a dose of 1-500mg once to several times a day in the case of a coating medicine, a suppository, etc. The 2,4-dihydroxybenzophenone is a known compound, and is obtained e.g. by the Friedel-Crafts reaction of resorcinol with benzoyl chloride. The antiinflammatory medicine is excellent in effectiveness and safety.
The invention discloses a water shield intelligence development health product. A preparation method of the water shield intelligence development health product comprises preparing water shield water extract, concentrating the water shield water extract to obtain water shield extract and adding accessory materials into the water shield extract to obtain a finished product. The water shield intelligence development health product is prepared from water shield water extract. Water shield contains natural zinc and calcium convenient for human body absorption, wherein calcium has a function of increasing bone density, is conducive to children growth and calcium supplement for the elderly, and is the optimal intelligence development health product for the elderly and children. Plant polyphenol can effectively reduce serum total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and atherosclerosis index (AI), has the function of reducing blood fat, and is a low calorie fat metabolism improving agent. The product is pure natural and has no toxic or side effect.
Pelvic organ prolapse (POP) is a major health concern, affecting more than 30% of women. Traditional vaginal surgery with native tissue is associated with high recurrence rate. Thus, synthetic meshes were introduced into POP surgery and became the mainstream. Several transvaginal mesh procedures, such as Uphold system (Boston Scientific) and Perigee system (American Medical Systems Inc), have been used for cystocele repair. Perigee system is a trans-obturator four-arm mesh device attached to proximal and distal arcus tendineus fasciae pelvis. Nonetheless, Uphold system, is a single incised, two-arm anterior sacrospinous mesh fixation system. Both systems can be used for cystocele repair, despite Uphold system can be used for concomitant repair of apical prolapse. The aim of this study was to compare the clinical outcomes of Uphold system and Perigee system in treating women with cystocele.
Surgical resection is considered to be the treatment of choice for Hepatocellular Carcinoma (HCC) combined with bile duct tumor thrombus (BDTT), but a significant proportion of patients with HCC combined with BDTT are unable to undergo surgical treatment at the time of initial diagnosis. For patients with unresectable advanced HCC combined with BDTT, conversion therapy is particularly important. Currently, there is relatively little literature related to the conversion treatment of HCC with BDTT. Several studies have confirmed that the transcatheter arterial chemoembolization (TACE), lenvatinib, combined with Tislelizumab (Triple Therapy) for the treatment of intermediate-advanced HCC can achieve better efficacy with an acceptable safety. However, there are no clinical studies or relevant literature reports on Triple Therapy for the treatment of HCC with BDTT. The present study is a multicenter, Single-arm, Real-world Study designed to evaluate the efficacy and safety of a triple therapy for the treatment of patients with HCC with BDTT.
Introduction: Emerging adulthood has been described as a period of risk for body weight gain. Several studies have indicated that the positive or negative health behaviors established during this stage, tend to prevail the rest of life. However, there are discrepancies in published studies on weight change in freshmen and there are disagreements on weight gain predictors. The present study reviewed the literature with the aim of knowing the eating behaviors associated with weight gain in university students. Method: A systematic search was conducted in three databases according to the PRISMA method during the months of February to November 2020. Results: 20 articles were included in the review. The main behaviors associated with weight gain were the consumption of sugary drinks, alcohol consumption, low consumption of vegetables and fruits, frequent self-consumption, eating unhealthy and low levels of food regulation.
OBJECTIVE: In carotid artery stenting (CAS) for internal carotid artery stenosis, the stent is often selected according to the plaque properties and arterial tortuosity. In our institute, an open-cell stent is used as the first-line stent regardless of the characteristics of the lesion. This study was performed to examine the outcome of CAS with an open-cell stent as the real-world results.
METHODS: In total, 811 CAS procedures using open-cell stents were performed for internal carotid artery stenosis from April 2002 to December 2019. Of these patients, we excluded those with hyperacute conditions for which CAS was performed within 3 days of onset, those in whom acute mechanical thrombectomy was performed simultaneously with CAS, and those with stenosis due to arterial dissection. Thus, 734 patients were retrospectively analyzed. Perioperative and long-term outcomes and risk factors for perioperative infarction were investigated.
RESULTS: The periprocedural stroke rate and mortality rate were 3.7% (27/734) and 0.4% (3/734), respectively. Low-echoic plaque was a significant risk factor for periprocedural stroke in both univariate (P < 0.03) and multivariate (odds ratio, 2.69; 95% confidence interval, 1.14-6.66; P = 0.02) analyses. Cerebral infarction and high grade restenosis were observed in 15 (2.0%) and 17 (2.3%) patients during a median 50-month follow-up.
CONCLUSIONS: CAS with open-cell stents showed good results in terms of both the postoperative stroke incidence and long-term severe restenosis rate. However, low-echoic plaque was a risk factor for perioperative stroke incidence, which should be considered when deciding on the indication for CAS with an open-cell stent.
Participants randomised to the control group will continue with their usual care for 8-weeks. They will return to repeat their baseline questionnaires and have their pelvic floor re-assessed. Finally, they will complete tSCS bladder filling and emptying cycles with urodynamics.
BACKGROUND: This report involves the first publication describing a case of parietal abdominal pain due to lower limb length discrepancy.
CASE PRESENTATION: A Caucasian male patient in his 50s was referred to our rehabilitation department with chronic abdominal pain that began in childhood. This chronic pain was associated with episodes of acute pain that were partially relieved by grade 3 analgesics. The patient was unable to sit for long periods, had recently lost his job, and was unable to participate in recreational activities with his children. Investigations revealed contracture and hypertrophy of the external oblique muscle and an limb length discrepancy of 3.8 cm (1.5 inches) in the left lower limb. The patient was effectively treated with a heel raise, physiotherapy, intramuscular injection of botulinum toxin, and lidocaine. The patient achieved the therapeutic goals of returning to work, and reducing analgesic use.
CONCLUSIONS: Structural misbalances, as may be caused by lower leg discrepancy, may trigger muscular compensations and pain. Complete anamnesis and clinical examination must not be trivialized and may reveal previously ignored information leading to a proper diagnosis.
The time-course of PAPs after application of Metvixia Cream has been monitored by means of fluorescence. After application of Metvixia Cream to actinic keratosis lesions in 8 patients, fluorescence was measured at several time points over 28 hours. Three hours after the application of Metvixia Cream the fluorescence in the treated lesions was significantly greater than that seen in both treated and untreated normal skin, and after application of vehicle cream (not containing methyl aminolevulinate) to normal skin. After application of Metvixia Cream for 28 hours and subsequent illumination with red light of 570 to 670 nm wavelength at a total light dose of 75 J/cm2, complete photobleaching (photodegradation) of Protoporphyrin IX occurred with levels of Protoporphyrin IX returning to pre-treatment values within 1 hour after illumination. However, the fate of other photoactive porphyrins are unknown.

The clinical dose of methyl aminolevulinate cream and duration of application were derived from a study in which three different strengths of the cream (16, 80 and 160 mg/g methyl aminolevulinate, as hydrochloride), each applied for 3 hours or 18 hours, were tested in 16 patients.
Plasma Enzymes: Elevation of liver enzymes (AST, ALT) have been reported in female patients exposed to ZOLADEX (representing less than 1% of all patients). 

Lipids: In a controlled trial, ZOLADEX therapy resulted in a minor, but statistically significant effect on serum lipids. In patients treated for endometriosis at 6 months following initiation of therapy, danazol treatment resulted in a mean increase in LDL cholesterol of 33.3 mg/dL and a decrease in HDL cholesterol of 21.3 mg/dL compared to increases of 21.3 and 2.7 mg/dL in LDL cholesterol and HDL cholesterol, respectively, for ZOLADEX-treated patients. Triglycerides increased by 8.0 mg/dL in ZOLADEX-treated patients compared to a decrease of 8.9 mg/dL in danazol-treated patients. 

In patients treated for endometriosis, ZOLADEX increased total cholesterol and LDL cholesterol during 6 months of treatment. However, ZOLADEX therapy resulted in HDL cholesterol levels which were significantly higher relative to danazol therapy. At the end of 6 months of treatment, HDL cholesterol fractions (HDL2 and HDL3) were decreased by 13.5 and 7.7 mg/dL, respectively, for danazol-treated patients compared to treatment increases of 1.9 and 0.8 mg/dL, respectively, for ZOLADEX-treated patients.
Marine biodegradable polymer particle groups according to the present invention comprise a polymer compound obtained by using two or more at least divalent metal cations to crosslink a water-soluble polymeric polyvalent anion that has a monovalent anionic substituent and includes at least a compound derived from alginic acid. The marine biodegradable polymer particle groups satisfy conditions (1)–(4). (1) The at least divalent metal cations are 3–30 mass% of the particle groups. (2) The difference between the maximum value and the minimum value of the atomic radii of the metal elements of the at least divalent metal cations is at least 15 Å. (3) The at least divalent metal cations of metal elements that have atomic radii of at least 150 Å are at least 25 mass% of all the at least divalent metal cations. (4) The water absorption of the particle groups is less than 300 mL/100 g.
The present invention relates to the use of alpha-ionoideoethane as an aromatic compound and to the use of an alpha-ionoideoethane synthase in the production of one or more aromatic compounds. The process of the present invention for preparing one or more aromatic compounds comprises: a) providing farnesyl diphosphate and the α -violet ethylene synthase under conditions suitable for the production of α -violet ethylene by the α -violet ethylene synthase as defined herein, b) converting farnesyl diphosphate to α -violet ethylene in vitro or in a host cell, c) optionally converting α -violet ethylene to one or more additional aromatic compounds, d) separating α -violet ethylene and the optionally one or more additional aromatic compounds, and e) optionally purifying α -violet ethylene and the optionally one or more additional aromatic compounds. The invention also relates to a method for perfuming a product, in particular for imparting and/or enhancing an odor or flavor, wherein at least one alpha-ionoideneaethane synthase is used. In addition, the present invention provides an aroma compound or composition and/or a fragrance composition and/or a perfumed or perfumed product comprising i) at least one alpha-ionoideoethane. The invention further includes a perfumed or perfumed product comprising at least the alpha-violet subunit ethane. The invention further relates to a process for the production of alpha-ionone (4- (2, 6-trimethylcyclohex-2-en-1-yl) but-3-en-2-one), comprising the steps in the following order: a) Contacting farnesyl diphosphate with at least one alpha-ionoideneaethane synthase under conditions suitable for the production of at least one alpha-ionoideneaethane; b) Producing the at least one alpha-ionoideoethane; c) Exposing the at least one alpha-ionone ethylene produced in step b) to conditions suitable for oxidative cleavage of the alpha-ionone ethylene to produce alpha-ionone; and d) optionally, isolating the alpha-ionone produced in step c). The invention also relates to a host cell for producing alpha-ionone (4- (2, 6-trimethylcyclohex-2-en-1-yl) butan-3-en-2-one), wherein the host cell comprises farnesyl diphosphate and a heterologous nucleic acid encoding an alpha-ionone ethylene synthase, wherein the host cell is capable of oxidative cleavage of alpha-ionone ethylene to produce alpha-ionone. Finally, the invention relates to the use of a host cell comprising farnesyl diphosphate and a heterologous nucleic acid encoding an alpha-ionoideneethane synthase for: (i) producing alpha-ionoideoethane; (ii) producing alpha-ionone; (iii) vitamin a production; (iv) Converting the alpha-ionone to alpha-ionone; (v) converting alpha-ionoidethane to vitamin a; (vi) for heterologous reconstitution of terpenes or terpenoids; (vii) for producing industrial products; (viii) a fermentation production system for producing sesquiterpenes.
Major depressive episodes (MDEs) occur frequently during the course of psychotic disorders, and several antidepressive agents have been successfully applied. The new melatonergic antidepressant agomelatine (AGO) appears promising for the treatment of MDEs in schizophrenia for several reasons: 1. AGO provides a unique pharmacological profile by combining antidepressive potency, sleep regulation and enhancement of frontocortical dopaminergic activity by 5-HT-2C-blockade. 2. AGO might exert favourable effects on cognition. 3. While pharmacokinetic interactions are generally possible, major influences on antipsychotic substances are unlikely due to metabolism by cytochrome isoenzymes CYP1A2 and CYP2C9/19. 4. AGO is characterized by a favourable range of adverse events (AE) which do not overlap with typical antipsychotic AEs such as weight gain and sexual dysfunction. Thus, the risk of additive effects seems to be small. The investigators plan to enroll 27 schizophrenic patients into an open, single-armed, prospective clinical trial with agomelatine. As predefined primary and secondary endpoints, we are going to investigate whether AGO is able to improve MDE severity, sleep quality, general and psychosocial functioning as well as cognitive function in schizophrenia without detrimental effects on the psychotic syndrome. Moreover, we intend to monitor for pharmacokinetic interactions. The results obtained will allow designing future randomized and controlled clinical trials in order to improve the range of therapeutic options for affective and cognitive deficits in schizophrenia.
Study 1: Zinc absorption studies The zinc study employed a 2-day cross-over design, labeling the WPS diet with a different zinc stable isotope (67Zn) than the control diet (70Zn). All meals during the 2-day period were labeled with tracer. The dual isotope ratio technique was used with a 3rd Zn stable isotope (68Zn) given intravenously and urine enrichment of all isotopes measured on Study Days 6-9 to measure fractional absorption of Zn (FAZ). The amount of Zn absorbed for the day was determined by multiplying the Zn intake for the day (determined from lab analyses of duplicate test meals) by the FAZ. Children (n=16) were randomized as to the order in which they consume the test and control meals on Study Day 1 and 2.

Study 2: Iron absorption studies The iron study was a cross sectional study with one group receiving control meals and the second group receiving the same control meal plus WPS. Iron absorption was measured using the erythrocyte iron incorporation technique with labeling of all meals over 2 days (58Fe). This was preceded by a reference dose of Fe57 and ascorbate on the previous day. Children (n=32) were randomized to receive the control diet or intervention diet (control diet + WPS).